<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is one of the most common systemic <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">disorders of connective tissue</z:e> with the incidence of approximately 2-3 per 10 000 individuals </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0003493" disease_type="Disease or Syndrome" abbrv="">Aortic disease</z:e>, leading to progressive aneurysmal <z:mpath ids='MPATH_66'>dilatation</z:mpath> and dissection is the main cause of morbidity and mortality of Marfan patients </plain></SENT>
<SENT sid="2" pm="."><plain>Current treatment (e.g. beta blockers and elective surgery) does postpone but cannot prevent aortic complications in these patients </plain></SENT>
<SENT sid="3" pm="."><plain>Recent studies have found transforming growth factor beta (TGF beta) to be involved in the <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> formation </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor blocker inhibits TGFbeta in a mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> leading to inhibition of aortic growth </plain></SENT>
<SENT sid="5" pm="."><plain>The main objective of this trial is to assess whether <z:chebi fb="0" ids="6541">losartan</z:chebi> treatment leads to a clinically relevant decrease of <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> in adult patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS/DESIGN: COMPARE study (COzaar in Marfan Patients Reduces aortic Enlargement) is an open-label, randomized, controlled trial with blinded end-points </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi> will be compared with no additional treatment after 3 years of follow-up </plain></SENT>
<SENT sid="8" pm="."><plain>We will enroll 330 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> who will be randomly assigned to receive <z:chebi fb="0" ids="6541">losartan</z:chebi> or not </plain></SENT>
<SENT sid="9" pm="."><plain>Patients taking beta-blockers will continue taking their standard treatment </plain></SENT>
<SENT sid="10" pm="."><plain>The primary end-point is the largest change in aortic diameter at any aortic level measured by means of MRI </plain></SENT>
<SENT sid="11" pm="."><plain>Secondary end-points are change in mortality, incidence of dissection, elective aortic surgery, aortic volume, aortic stiffness and ventricular function </plain></SENT>
<SENT sid="12" pm="."><plain>We will also investigate gene and protein expression change in the skin under <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy and create prediction models for <z:chebi fb="0" ids="6541">losartan</z:chebi>-treatment response and <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>DISCUSSION: The COMPARE study will provide important evidence of effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> treatment in adult Marfan patient population </plain></SENT>
<SENT sid="14" pm="."><plain>We expect <z:chebi fb="0" ids="6541">losartan</z:chebi> to significantly reduce the occurrence and progression of <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>This trial investigates a wide spectrum of clinical, genetic and biochemical effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> aiming to provide further insight in the pathogenesis and treatment of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>TRIAL REGISTRATION: Netherlands Trial Register NTR1423 </plain></SENT>
</text></document>